Comparison of Relative Change with Effect Size Metrics in Alzheimer’s Disease Anti‐amyloid Clinical Trials
Terry E Goldberg, Seonjoo Lee, Davangere Devanand, Lon S S Schneider · 2025
Read Comparison of Relative Change with Effect Size Metrics in Alzheimer’s Disease Anti‐amyloid Clinical Trials by Terry E Goldberg, Seonjoo Lee, Davangere Devanand, Lon S S Schneider (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712851.txt.
Description
Terry E Goldberg and co-authors published a research paper in 2025 on how drug trial results for Alzheimer's disease should be measured and reported. Trials often brag about percent slowing of decline. The team argues that this figure can mislead, because it swings with how fast the dummy-drug group happens to fall.
They compared percent slowing with a standard effect size and with the number of patients one must treat to help one person. In recent antibody trials, effect sizes were small while percent slowing looked fair, and the number needed to treat ran high. The authors urge readers to weigh the standard measure before trusting headline percentages.
Catalog record
| CREATOR | Terry E Goldberg, Seonjoo Lee, Davangere Devanand, Lon S S Schneider |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |